

Attorney Docket No. 13

NAY 0 6 2002 SANTER 1600/29

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)	Group Art Unit:	300/ <b>2900</b>	002
WANG, et. al.	)	Examiner: Not Assigned	90	
Serial No.: 09/888,840	)	I HEREBY CERTIFY THAT THIS CORFESPO IS BEING DEPOSITED WITH THE U.S. PC	NDENCE STAL	
Filed: June 25 2001	)	SERVICE AS FIRST CLASS MAIL IN AN EN ADDRESSED TO: COMMISSIONER OF RATE TRADEMARKS, MASHINGTON, AC 2020	VELOPE NTS AND SE ON Z	ae)
For: ARYL PHENYLHETEROCYCLYL SULFIDE DERIVATES AND THEIR USE AS CELL ADHESION-INHIBITING ANTI-INFLAMMATORY AND IMMUNE SUPPRESSIVE AGENTS	))))))	Pasadena, California		

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D. C. 20231

Sir:

Attached is a Form PTO-1449 listing documents cited in the International Search Report from the corresponding application and believed to be relevant to the above-identified application. It is respectfully requested that these documents be considered by the Examiner and an initialled copy of the form be returned to the undersigned.

It should be noted that the word "prior" has been deleted from the form.

It is believed that this disclosure complies with the requirements of 37 C.F.R. 1.56 and the Manual of Patent Examining Procedures Section 707.05(b). If for some reason

Attorney Docket No. 13780-2

the Examiner considers otherwise, it is respectfully requested that the undersigned be called so that any deficiencies can be promptly remedied.

Some part of the documents may have markings thereon. No significance is meant to be attached to the markings.

No. fee is believed due in connection with this communication. However, if it is determined that a fee is due, the Commissioner is hereby authorized to charge payment of any additional fees, in particular the following fees, associated with this communication, or credit any overpayment to Deposit Account No. 19-2090:

Respectfully submitted,

SHELDON & MAK a Professional Corporation

Reg. No. 9-50,139

225 South Lake Avenue 9th Floor Pasadena, CA 91101 626/796-4000

MINORMATION DISCLOSURE CITATION	Docket Nu	mber 13780-2		Application Nu	mber 09/8	88,840		
(Dse Soveral sheets if necessary)	Applicant(s	B) WANG ET AL.					· · · · · ·	
APR 1 6 2002 (5)	Filing Date	June 25, 2001		G	roup Årt U	nit		
PADOMEN SEE		U.S. PATENT DOC	UMENTS					4 - 4 4 - 4 4 - 44
*EXAMINER REF DOCUMENT NUMBER INITIAL*		DATE	NAME	:	CLASS	SUBCLASS	FILING D	
A 4,973,599		11/27/90	Gilman e	et al.				
B 5,028,629		07/02/91	Lilly et	al.				
C 5,776,951		07/07/98_	Arrowsmith	n et al.				N
D 5,883,106	_	03/16/99	Stevens o	et al.		9	3	<u>m</u>
E 5,883,133		03/16/99	Schwark	et al.		9	2 E	
F 5,912,266		06/15/99	Perez	2			MY DO LOU	
G 6,110,992		8/29/2000	Wada et	t al.			3/6	700
H 6,110,922		8/29/2000	Link et	al.			00	2
I S/N 09/285,477						·	306	
J S/N 09/285,325								
	FO	REIGN PATENT DO	CUMENTS			· -		
							TRANSLA	TION
DOCUMENT NUMBER		DATE	COUNT	RY	CLASS	SUBCLASS	YES	N
K DE 2123383		12/2/71	Germa	ny		<u> </u>		
L GB 2 117 760 A		10/19/93	United Kin	ngdon				
M EP 0219756		10/6/86	EPO					
N JP 12072766		03/07/2000	Japar	n				
O W098/13347		04/02/98	PCT					
P W098/39303		9/11/1998	PCT					
Q W099/11258		03/11/1999	PCT					
R W099/20617		4/29/1999	РСТ					
S W099/20618		4/29/1999	PCT					
T W099/49856		10/07/1999	PCT					$\prod$
U W000/15604		3/23/2000	PCT					
V W000/15645		3/23/2000	РСТ					
W W000/21920		04/20/200	PCT					
X W000/48989		08/24/2000	PCT					$\top$
Y W000/59878		10/12/2000	PCT					11
Z W000/60355		.10/12/2000	PCT					$\dagger \dagger$
AA WO01/06984		2/1/2001	PCT					11
AB W001/07052		2/1/2001	PCT	<del></del>				+-
AC W001/27102		4/19/2000	PCT					十一
	ART (Includ	ding Author, Title, I			<del></del>	•		

			Sheet 2 o
1	MAK 1 0	7002 S	Ali, H. et al., Mechanisms of Inflammation and Leukocyte Activation, Med. Clin. North America (1997) 81:1-28
Y	ENT & TRAD	MAR	Bella, J., et al. The Structure of the Two Amino-terminal Domains of Human ICAM-1 Suggests How it Functions as a Rhinovirus Receptor and As An LFA-1 Integrin Ligand. (1998) Proc. Natl. Acad. Sci. USA 95:4140-4145.
L	٠	AF	Binnerts, M.E., et al. How LFA-1 Binds to Different Ligands. (1999) Immunol Today 20:240-245.
		AG	Boschelli, D.H., et al. Inhibition of E-Selectin-, ICAM-1-, and VCAM-1-Mediated Cell Adhesion by Benzo[b]thiophene-, Benzofuran-, Indole-, and Naphthalene-2-Carboxamides: Identification of PD 144795 as an Antiinflammatory Agent. ((1995) J. Med. Chem. 38:4597-4614.
		АН	Carlos, T.M., Leukocyte-Endothelial Adhesion Molecules. Blood (1994) 84:2068-2101
		ΑI	Edwards, C.P. et al., Mapping the Intercellular Adhesion Molecule-1 and -2 Binding Site on the Inserted Domain of Leukocyte Function-associated Antigen-1. (1998) J. Biol. Chem. 273:28937-28944.
		AJ	Fisher, K.L., et al., Identification of the Binding Site in Intercellular Adhesion Molecule 1 for its Receptor, Leukocyte Functionassociated Antigen 1. (1997) Mol. Biol. Cell 8:501-515.
		AK	Gadek, T.R., et al., Identification and Characterization of Antagonists of the LFA-1/ICAM-1 Protein-Protein Interaction as Novel Immunomodulatory Agents. 220th ACS National Meeting, Washington, D.C., USA (2000) MEDI 177
		AL	Gahmberg, C.G., Leukocyte Adhesion: CD11/CD18 Integrins and Intercullular Adhesion Molecules, Curr. Opin. Cell Biol. (1997) 9:643-650
		АМ	Gahmberg, C.G., Leukocyte Adhesion: Structure and Function of Human Leukocyte $\beta_2$ -integrins and Their Cellular Ligands. (1997) Eur. J. Biochem. 245:215-232.
		AN	Green, J.M., T Cell Receptor Stimulation, But Not CD28 Costimulation, Is Dependent on LFA-1-Mediated Events, Eur J. Immunology (1994) 24:265-272
		AO	Hamilton, G.S., et al., Fluorenylalkanoic and Benzoic Acids as Novel Inhibitors of Cell Adhesion Processes in Leukocytes. (1995) 38:1650-1656.
		АР	Henricks, P.A., Pharmacological modulation of cell adhesion molecules, Eur. J. Pharmacol. (1998) 344:1-13
		DA	Huang, C., A Binding Interface on the I Domain of Lymphocyte Function-associated Antigen-1 (LFA-1) Required for Specific Interaction with Intercellular Adhesion Molecule 1 (ICAM-1), (1995) 270:19008-19016
L		AR	Huth, J.R., NMR and Mutagenesis Evidence for an I Domain Allosteric Site That Regulates Lymphocyte Function-associated Antigen 1 Ligand Binding. Proc. Natl. Acad. Sci, USA (2000) 97:5231-5236.
		AS	Kallen, J., et al., Structural Basis for LFA-1 Inhibition upon Lovastatin Binding to the CD11a I-Domain, J. Mol. Biol. (1999) 292-1-9
		AT	Kelly, T.A., Cutting Edge: A Small Molecule Antagonist of LFA-1-Mediated Cell Adhesion, J. Immunol. (1999) 163:5173-5177
		AU	Kishimoto, T.K., Integrins, ICAMs and Selectins: Role and Regulation of Adhesion Molecules in Neutrophil Recruitment to Inflammatory Sites, Adv. Pharmacol. (1994) 25:117-169
L		AV	Landis, R.C. Involvement of The "I" domain of LFA-1 in Selective Binding to Ligands ICAM-I and ICAM-3, J. Cell Biol. (1994) 126:529-537
		AW	Link, J.T., et al., Discovery and SAR of Diarylsulfide Cyclopropylamide LFA-1/ICAM-1 Interaction Antagonists. Bioorg. Med. Cehm Lett. (2001) 11:973-976
		АХ	Liu, G., Small Molecule Antagonists of the LFA-1/ICAM-1 Interaction as Potential Therapeutic Agents, Expert Opin. Ther.Patents (2001) 11(9) 1383-1393.
	,	AY	Liu, G., et al., Discovery of Novel P-arylthio Cinnamides as Antogonists of Leukocyte Function-associated Antigen-1/intracellular Adhesion Molecule-1 Interaction, 1. Identification of an Additional Binding Pocket Based on an Anilino Diaryl Sulfide Lead. J. Chem. (2000) 43:4025-4040
		AZ	Liu, G., et al., Novel P-arylthio Cinnamides as Antagonists of Leukocyte Function-associated Antigen-1/intracellular Adhesion Molecule-1 Interaction. 2. Mechanism of Inhibition and Structure-based Improvement of Pharmaceutical Properties. (2001) J. Med. Chem. 44:1202-1210.
		ВА	Lu, C., et al., An Isolated, Surface-expressed I Domain of the Integrin Alβ2 Is Sufficient for Strong Adhesive Function When Logical in the Open Conformation with a Disulfide Bond. Proc. Natl. Acad. Sci. USA (2001) 98-2387-2392
		88	Nakano, T., et al., Adxanthromycins A and B, New Inhibitors of ICAM-1/ILFA-1 Mediated Cell Adhesion Molecule from Streptomyces sp NA-148, J. Antibos. (Tokyo) (2000) 53:12-18

<u>~~</u>	Silect of
\$C55	Pei, Z., et al., Discovery of Potent Antagonists of Leukocyte Function-associated Antigen-1/intercellular Adhesion Molecule-1 Interaction. 3. Amide (C-ring) Structure-activity Relationship and Improvement of Overall Properties of Arylthio Cinnamides. J. Med. Chem. (2001) In press.
(1)%D	Qu, A., et al., The Role of the Divalent Cation in the Structure of the I Domain from the CD11a/CD18 Integrin. (1996) Structure 4:931-942.
BE	Sanfilippo, P.J. Novel Thiazole Based Heterocycles as Inhibitors of LFA-1/ICAM-1 Mediated Cell Adhesion, J. Med. Chem. (1995) 38:1057-1059
BF	Springer, T.A., Adhesion Receptors of the Immune System, Nature (1990) 346:425-434
BG	Stanley, P., et al., The I Domain of Integrin LFA-1 interacts with ICAM-1 Domain 1 at Residue Glu-34 But Not Gln-73. (1998) J. Biol. Chem. 273:3358-3362.
	BE BF

**EXAMINER** 

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.